{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:31:18Z","timestamp":1791412278125,"version":"4.3.3"},"reference-count":127,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.intimp.2017.11.005","type":"journal-article","created":{"date-parts":[[2017,11,10]],"date-time":"2017-11-10T15:45:38Z","timestamp":1510328738000},"page":"131-138","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":85,"special_numbering":"C","title":["Sixteen-year history of rituximab therapy for 1085 pemphigus vulgaris patients: A systematic review"],"prefix":"10.1016","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6765-8830","authenticated-orcid":false,"given":"Soheil","family":"Tavakolpour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HamidReza","family":"Mahmoudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamran","family":"Balighi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robabeh","family":"Abedini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Daneshpazhooh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.intimp.2017.11.005_bb0005","first-page":"108","article-title":"Epidemiology of pemphigus in Tehran, Iran: a 20-year retrospective study","volume":"1","author":"Abdolsamadi","year":"2007","journal-title":"J. Dent. Res. Dent. Clin. Dent. Prospects"},{"issue":"6","key":"10.1016\/j.intimp.2017.11.005_bb0010","first-page":"1109","article-title":"Incidence of pemphigus vulgaris exceeds that of pemphigus foliaceus in a region where pemphigus foliaceus is endemic: analysis of a 21-year historical series","volume":"86","author":"Goncalves","year":"2011","journal-title":"An. Bras. Dermatol."},{"issue":"3","key":"10.1016\/j.intimp.2017.11.005_bb0015","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/jdv.12772","article-title":"Pemphigus. S2 guideline for diagnosis and treatment\u2014guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV)","volume":"29","author":"Hertl","year":"2015","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.intimp.2017.11.005_bb0020","article-title":"Anti-interleukin and associated receptors monoclonal antibodies therapy in autoimmune diseases","volume":"3","author":"Tavakolpour","year":"2016","journal-title":"Receptors Clin. Investig."},{"issue":"5 Suppl 14","key":"10.1016\/j.intimp.2017.11.005_bb0025","first-page":"66","article-title":"Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma","volume":"26","author":"Grillo-Lopez","year":"1999","journal-title":"Semin. Oncol."},{"issue":"4","key":"10.1016\/j.intimp.2017.11.005_bb0030","first-page":"325","article-title":"Targeted therapies in rheumatoid arthritis: focus on rituximab","volume":"1","author":"Teng","year":"2007","journal-title":"Biologics"},{"issue":"4","key":"10.1016\/j.intimp.2017.11.005_bb0035","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/jdv.12678","article-title":"An assessment of treatment history and its association with clinical outcomes and relapse in 155 pemphigus patients with response to a single cycle of rituximab","volume":"29","author":"Amber","year":"2015","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"5","key":"10.1016\/j.intimp.2017.11.005_bb0040","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/j.1365-2133.2007.07800.x","article-title":"Rituximab in the adjuvant treatment of pemphigus vulgaris: a prospective open-label pilot study in five patients","volume":"156","author":"Goh","year":"2007","journal-title":"Br. J. Dermatol."},{"issue":"3","key":"10.1016\/j.intimp.2017.11.005_bb0045","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1080\/09546630701286110","article-title":"Treatment of refractory pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab): five cases","volume":"18","author":"Antonucci","year":"2007","journal-title":"J. Dermatolog. Treat."},{"issue":"3","key":"10.1016\/j.intimp.2017.11.005_bb0050","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jaad.2012.08.010","article-title":"Successful treatment of pemphigus with biweekly 1-g infusions of rituximab: a retrospective study of 47 patients","volume":"68","author":"Leshem","year":"2013","journal-title":"J. Am. Acad. Dermatol."},{"issue":"3","key":"10.1016\/j.intimp.2017.11.005_bb0055","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1111\/bjd.13823","article-title":"Paradoxical worsening of pemphigus vulgaris following rituximab therapy","volume":"173","author":"Feldman","year":"2015","journal-title":"Br. J. Dermatol."},{"issue":"4","key":"10.1016\/j.intimp.2017.11.005_bb0060","doi-asserted-by":"crossref","first-page":"389","DOI":"10.4103\/0378-6323.174379","article-title":"Clinical efficacy of rituximab in the treatment of pemphigus: a retrospective study","volume":"82","author":"Sharma","year":"2016","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"issue":"2","key":"10.1016\/j.intimp.2017.11.005_bb0065","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1001\/jamadermatol.2014.2421","article-title":"First-line treatment of pemphigus vulgaris with a combination of rituximab and high-potency topical corticosteroids","volume":"151","author":"Ingen-Housz-Oro","year":"2015","journal-title":"JAMA Dermatol."},{"issue":"10083","key":"10.1016\/j.intimp.2017.11.005_bb0070","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.intimp.2017.11.005_bb0075","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1067\/mjd.2002.126273","article-title":"Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder","volume":"47","author":"Salopek","year":"2002","journal-title":"J. Am. Acad. Dermatol."},{"issue":"4","key":"10.1016\/j.intimp.2017.11.005_bb0080","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1046\/j.1365-2230.2003.01283.x","article-title":"Treatment of resistant pemphigus vulgaris with an anti-CD20 monoclonal antibody (Rituximab)","volume":"28","author":"Cooper","year":"2003","journal-title":"Clin. Exp. Dermatol."},{"issue":"3","key":"10.1016\/j.intimp.2017.11.005_bb0085","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1046\/j.1365-2133.2003.05209_10.x","article-title":"Treatment of pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab)","volume":"148","author":"Herrmann","year":"2003","journal-title":"Br. J. Dermatol."},{"issue":"7","key":"10.1016\/j.intimp.2017.11.005_bb0090","article-title":"Anti-CD20 monoclonal antibody (rituximab) in the treatment of autoimmune diseases. Successful result in refractory pemphigus vulgaris: report of a case","volume":"88","author":"Virgolini","year":"2003","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.intimp.2017.11.005_bb0095","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1001\/archderm.140.1.91","article-title":"Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody)","volume":"140","author":"Dupuy","year":"2004","journal-title":"Arch. Dermatol."},{"issue":"6","key":"10.1016\/j.intimp.2017.11.005_bb0100","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.jaad.2003.08.021","article-title":"Long-term complete remission of severe pemphigus vulgaris with monoclonal anti-CD20 antibody therapy and immunophenotype correlations","volume":"50","author":"Espana","year":"2004","journal-title":"J. Am. Acad. Dermatol."},{"issue":"5","key":"10.1016\/j.intimp.2017.11.005_bb0105","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.jaad.2004.06.007","article-title":"Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab)","volume":"51","author":"Morrison","year":"2004","journal-title":"J. Am. Acad. Dermatol."},{"issue":"2","key":"10.1016\/j.intimp.2017.11.005_bb0110","first-page":"185","article-title":"Successful rituximab treatment of severe pemphigus vulgaris resistant to multiple immunosuppressants","volume":"85","author":"Wenzel","year":"2005","journal-title":"Acta Derm. Venereol."},{"issue":"2","key":"10.1016\/j.intimp.2017.11.005_bb0115","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/j.1365-2133.2005.06740.x","article-title":"Long-standing remission of recalcitrant juvenile pemphigus vulgaris after adjuvant therapy with rituximab","volume":"153","author":"Schmidt","year":"2005","journal-title":"Br. J. Dermatol."},{"issue":"3","key":"10.1016\/j.intimp.2017.11.005_bb0120","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/j.1365-2133.2005.06651.x","article-title":"Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus","volume":"153","author":"Arin","year":"2005","journal-title":"Br. J. Dermatol."},{"issue":"5","key":"10.1016\/j.intimp.2017.11.005_bb0125","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1525-1470.2005.00118.x","article-title":"Successful treatment of refractory childhood pemphgus vulgaris with anti-CD20 monoclonal antibody (rituximab)","volume":"22","author":"Kong","year":"2005","journal-title":"Pediatr. Dermatol."},{"issue":"1","key":"10.1016\/j.intimp.2017.11.005_bb0130","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.1365-2230.2005.01941.x","article-title":"Response of pemphigus vulgaris to anti-CD20 antibody therapy (rituximab) may be delayed","volume":"31","author":"Belgi","year":"2006","journal-title":"Clin. Exp. Dermatol."},{"issue":"1","key":"10.1016\/j.intimp.2017.11.005_bb0135","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2340\/00015555-0007","article-title":"Long-lasting remission of pemphigus vulgaris treated with rituximab","volume":"86","author":"Esposito","year":"2006","journal-title":"Acta Derm. Venereol."},{"issue":"3","key":"10.1016\/j.intimp.2017.11.005_bb0140","first-page":"266","article-title":"Delayed response of oral pemphigus vulgaris to rituximab treatment","volume":"16","author":"Niedermeier","year":"2006","journal-title":"Eur. J. Dermatol."},{"issue":"17","key":"10.1016\/j.intimp.2017.11.005_bb0145","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1056\/NEJMoa062930","article-title":"Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin","volume":"355","author":"Ahmed","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.intimp.2017.11.005_bb0150","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa067752","article-title":"A single cycle of rituximab for the treatment of severe pemphigus","volume":"357","author":"Joly","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.intimp.2017.11.005_bb0155","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1080\/09546630701323988","article-title":"Prolonged treatment with rituximab in patients with refractory pemphigus vulgaris","volume":"18","author":"Barrera","year":"2007","journal-title":"J. Dermatolog. Treat."},{"issue":"6","key":"10.1016\/j.intimp.2017.11.005_bb0160","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1111\/j.1365-2133.2007.08189.x","article-title":"Late-onset neutropenia following rituximab treatment in patients with autoimmune diseases","volume":"157","author":"Rios-Fernandez","year":"2007","journal-title":"Br. J. Dermatol."},{"issue":"4","key":"10.1016\/j.intimp.2017.11.005_bb0165","first-page":"335","article-title":"Rituximab therapy in severe juvenile pemphigus vulgaris","volume":"80","author":"Mamelak","year":"2007","journal-title":"Cutis"},{"issue":"2","key":"10.1016\/j.intimp.2017.11.005_bb0170","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/j.1365-2133.2007.08358.x","article-title":"Treatment of severe pemphigus with protein A immunoadsorption, rituximab and intravenous immunoglobulins","volume":"158","author":"Shimanovich","year":"2008","journal-title":"Br. J. Dermatol."},{"issue":"3","key":"10.1016\/j.intimp.2017.11.005_bb0175","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1468-3083.2007.02340.x","article-title":"Treatment failure with rituximab in a patient with pemphigus vulgaris","volume":"22","author":"Weger","year":"2008","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"3","key":"10.1016\/j.intimp.2017.11.005_bb0180","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1365-4632.2008.03423.x","article-title":"Two courses of rituximab (anti-CD20 monoclonal antibody) for recalcitrant pemphigus vulgaris","volume":"47","author":"Faurschou","year":"2008","journal-title":"Int. J. Dermatol."},{"issue":"6","key":"10.1016\/j.intimp.2017.11.005_bb0185","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.jbspin.2007.10.010","article-title":"Polymyositis and pemphigus vulgaris in a patient: successful treatment with rituximab","volume":"75","author":"Tournadre","year":"2008","journal-title":"Joint Bone Spine"},{"issue":"Suppl. 1","key":"10.1016\/j.intimp.2017.11.005_bb0190","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1111\/j.1529-8019.2008.00194.x","article-title":"Rituximab in refractory pemphigus vulgaris","volume":"21","author":"Sorce","year":"2008","journal-title":"Dermatol. Ther."},{"issue":"3","key":"10.1016\/j.intimp.2017.11.005_bb0195","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1159\/000187431","article-title":"Clinical and immunological follow-up of pemphigus patients on adjuvant treatment with immunoadsorption or rituximab","volume":"218","author":"Pfutze","year":"2009","journal-title":"Dermatology"},{"issue":"1","key":"10.1016\/j.intimp.2017.11.005_bb0200","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1365-2133.2009.09204.x","article-title":"Haemolytic anaemia following rituximab treatment in a patient with pemphigus vulgaris","volume":"161","author":"Li","year":"2009","journal-title":"Br. J. Dermatol."},{"issue":"3","key":"10.1016\/j.intimp.2017.11.005_bb0205","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.clim.2009.05.007","article-title":"Immunogenicity of rituximab in patients with severe pemphigus","volume":"132","author":"Schmidt","year":"2009","journal-title":"Clin. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2017.11.005_bb0210","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jaad.2010.02.052","article-title":"Therapeutic ladder for pemphigus vulgaris: emphasis on achieving complete remission","volume":"64","author":"Strowd","year":"2011","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.intimp.2017.11.005_bb0215","doi-asserted-by":"crossref","first-page":"321950","DOI":"10.1155\/2010\/321950","article-title":"Targeted immunotherapy with rituximab leads to a transient alteration of the IgG autoantibody profile in pemphigus vulgaris","volume":"2010","author":"Muller","year":"2010","journal-title":"Dermatol. Res. Pract."},{"issue":"1","key":"10.1016\/j.intimp.2017.11.005_bb0220","first-page":"27","article-title":"Successful immunoapheresis of bullous autoimmune diseases: pemphigus vulgaris and pemphigoid gestationis","volume":"9","author":"Marker","year":"2011","journal-title":"J. Dtsch. Dermatol. Ges."},{"issue":"2","key":"10.1016\/j.intimp.2017.11.005_bb0225","first-page":"202","article-title":"Dermatologic rituximab dosing: treatment of refractory pemphigus vulgaris in an adolescent male","volume":"10","author":"Stephens","year":"2011","journal-title":"J. Drugs Dermatol."},{"issue":"8","key":"10.1016\/j.intimp.2017.11.005_bb0230","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/j.1600-0714.2011.01017.x","article-title":"Rituximab for the treatment of corticosteroid-refractory pemphigus vulgaris with oral and skin manifestations","volume":"40","author":"Craythorne","year":"2011","journal-title":"J. Oral Pathol. Med."},{"issue":"3","key":"10.1016\/j.intimp.2017.11.005_bb0235","doi-asserted-by":"crossref","first-page":"R75","DOI":"10.1186\/ar3337","article-title":"Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID)","volume":"13","author":"Tony","year":"2011","journal-title":"Arthritis Res. Ther."},{"issue":"3","key":"10.1016\/j.intimp.2017.11.005_bb0240","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/j.1365-2133.2011.10411.x","article-title":"Clinical efficacy of different doses of rituximab in the treatment of pemphigus: a retrospective study of 27 patients","volume":"165","author":"Kim","year":"2011","journal-title":"Br. J. Dermatol."},{"issue":"3","key":"10.1016\/j.intimp.2017.11.005_bb0245","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.jaad.2010.07.032","article-title":"Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients","volume":"65","author":"Kasperkiewicz","year":"2011","journal-title":"J. Am. Acad. Dermatol."},{"issue":"1","key":"10.1016\/j.intimp.2017.11.005_bb0250","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1365-2133.2011.10585.x","article-title":"Treatment of severe pemphigus with a combination of immunoadsorption, rituximab, pulsed dexamethasone and azathioprine\/mycophenolate mofetil: a pilot study of 23 patients","volume":"166","author":"Kasperkiewicz","year":"2012","journal-title":"Br. J. Dermatol."},{"issue":"3","key":"10.1016\/j.intimp.2017.11.005_bb0255","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1365-2133.2011.10658.x","article-title":"Comparison of immunological parameters in patients with pemphigus vulgaris following rituximab and IVIG therapy","volume":"166","author":"Feldman","year":"2012","journal-title":"Br. J. Dermatol."},{"issue":"2","key":"10.1016\/j.intimp.2017.11.005_bb0260","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1365-2133.2011.10663.x","article-title":"Low-dose rituximab is effective in pemphigus","volume":"166","author":"Horvath","year":"2012","journal-title":"Br. J. Dermatol."},{"issue":"5","key":"10.1016\/j.intimp.2017.11.005_bb0265","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.jaad.2010.06.033","article-title":"Rituximab used as a first-line single agent in the treatment of pemphigus vulgaris","volume":"65","author":"Craythorne","year":"2011","journal-title":"J. Am. Acad. Dermatol."},{"issue":"2","key":"10.1016\/j.intimp.2017.11.005_bb0270","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1159\/000332848","article-title":"Long-term prognosis of pemphigus in Korea: retrospective analysis of 199 patients","volume":"223","author":"Kim","year":"2011","journal-title":"Dermatology"},{"issue":"4","key":"10.1016\/j.intimp.2017.11.005_bb0275","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/j.1365-2133.2011.10732.x","article-title":"Combined treatment with immunoadsorption and rituximab leads to fast and prolonged clinical remission in difficult-to-treat pemphigus vulgaris","volume":"166","author":"Behzad","year":"2012","journal-title":"Br. J. Dermatol."},{"issue":"1","key":"10.1016\/j.intimp.2017.11.005_bb0280","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1111\/j.1468-3083.2011.04391.x","article-title":"Efficacy and safety of rituximab treatment in Indian pemphigus patients","volume":"27","author":"Kanwar","year":"2013","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"4","key":"10.1016\/j.intimp.2017.11.005_bb0285","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.jaad.2011.11.007","article-title":"Therapy with rituximab for autoimmune pemphigus: results from a single-center observational study on 42 cases with long-term follow-up","volume":"67","author":"Cianchini","year":"2012","journal-title":"J. Am. Acad. Dermatol."},{"issue":"4","key":"10.1016\/j.intimp.2017.11.005_bb0290","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.jaad.2011.12.019","article-title":"Rituximab treatment of severe pemphigus: long-term results including immunologic follow-up","volume":"67","author":"Reguiai","year":"2012","journal-title":"J. Am. Acad. Dermatol."},{"issue":"6","key":"10.1016\/j.intimp.2017.11.005_bb0295","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1001\/archdermatol.2011.3320","article-title":"Effect of a single-cycle alternative dosing regimen for rituximab for recalcitrant pemphigus: a case series of 9 patients","volume":"148","author":"Matsukura","year":"2012","journal-title":"Arch. Dermatol."},{"issue":"3","key":"10.1016\/j.intimp.2017.11.005_bb0300","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jaci.2012.03.022","article-title":"Inhibitory human antichimeric antibodies to rituximab in a patient with pemphigus","volume":"130","author":"Lunardon","year":"2012","journal-title":"J. Allergy Clin. Immunol."},{"issue":"10","key":"10.1016\/j.intimp.2017.11.005_bb0305","first-page":"727","article-title":"Efficacy and safety of rituximab in pemphigus: experience of the German Registry of Autoimmune Diseases","volume":"10","author":"Kasperkiewicz","year":"2012","journal-title":"J. Dtsch. Dermatol. Ges."},{"issue":"6","key":"10.1016\/j.intimp.2017.11.005_bb0310","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1111\/j.1532-5415.2012.03987.x","article-title":"Pemphigus in elderly adults: clinical presentation, treatment, and prognosis","volume":"60","author":"Ingen-Housz-Oro","year":"2012","journal-title":"J. Am. Geriatr. Soc."},{"issue":"9","key":"10.1016\/j.intimp.2017.11.005_bb0315","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1001\/archdermatol.2012.1522","article-title":"Adjuvant rituximab therapy of pemphigus: a single-center experience with 31 patients","volume":"148","author":"Lunardon","year":"2012","journal-title":"Arch. Dermatol."},{"issue":"2","key":"10.1016\/j.intimp.2017.11.005_bb0320","doi-asserted-by":"crossref","first-page":"200","DOI":"10.2340\/00015555-1429","article-title":"Concurrent cytomegalovirus and herpes simplex virus infection in pemphigus vulgaris treated with rituximab and prednisolone","volume":"93","author":"Chiu","year":"2013","journal-title":"Acta Derm. Venereol."},{"issue":"5","key":"10.1016\/j.intimp.2017.11.005_bb0325","doi-asserted-by":"crossref","first-page":"632","DOI":"10.4103\/0378-6323.100587","article-title":"Childhood pemphigus vulgaris successfully treated with rituximab","volume":"78","author":"Kanwar","year":"2012","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"key":"10.1016\/j.intimp.2017.11.005_bb0330","doi-asserted-by":"crossref","unstructured":"I. Fuertes, A. Guilabert, J.M. Mascaro, Jr., P. Iranzo, Rituximab in childhood pemphigus vulgaris: a long-term follow-up case and review of the literature, Dermatology 221(1) (2010) 13-6.","DOI":"10.1159\/000287254"},{"issue":"2","key":"10.1016\/j.intimp.2017.11.005_bb0335","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/jdv.12080","article-title":"Clinical experiences of different dosing schedules of rituximab in pemphigus with various disease severities","volume":"28","author":"Cho","year":"2014","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"3","key":"10.1016\/j.intimp.2017.11.005_bb0340","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/mus.23657","article-title":"Myasthenia gravis, Castleman disease, pemphigus, and anti-phospholipid syndrome","volume":"47","author":"Jakubikova","year":"2013","journal-title":"Muscle Nerve"},{"issue":"2","key":"10.1016\/j.intimp.2017.11.005_bb0345","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1111\/hae.12087","article-title":"Acquired haemophilia treated successfully with rituximab in a patient with pemphigus vulgaris","volume":"19","author":"Chiba","year":"2013","journal-title":"Haemophilia"},{"issue":"4","key":"10.1016\/j.intimp.2017.11.005_bb0350","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1365-4632.2010.04870.x","article-title":"Recalcitrant pemphigus vulgaris: aseptic meningitis associated with intravenous immunoglobulin therapy and successful treatment with rituximab","volume":"52","author":"Ventura","year":"2013","journal-title":"Int. J. Dermatol."},{"issue":"175","key":"10.1016\/j.intimp.2017.11.005_bb0355","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3005166","article-title":"Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell response","volume":"5","author":"Colliou","year":"2013","journal-title":"Sci. Transl. Med."},{"issue":"6","key":"10.1016\/j.intimp.2017.11.005_bb0360","doi-asserted-by":"crossref","first-page":"427","DOI":"10.3109\/09546634.2013.784391","article-title":"Adjuvant rituximab therapy in pemphigus: a single-center experience of 18 cases","volume":"24","author":"Baum","year":"2013","journal-title":"J. Dermatolog. Treat."},{"issue":"1","key":"10.1016\/j.intimp.2017.11.005_bb0365","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00403-013-1355-4","article-title":"A prospective study on clinical response and cell-mediated immunity of pemphigus patients treated with rituximab","volume":"306","author":"Leshem","year":"2014","journal-title":"Arch. Dermatol. Res."},{"issue":"6","key":"10.1016\/j.intimp.2017.11.005_bb0370","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/jdv.12175","article-title":"Treatment of severe autoimmune blistering skin diseases with combination of protein A immunoadsorption and rituximab: a protocol without initial high dose or pulse steroid medication","volume":"28","author":"Kolesnik","year":"2014","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"1","key":"10.1016\/j.intimp.2017.11.005_bb0375","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1016\/j.jaad.2012.12.967","article-title":"Successful single-cycle rituximab treatment in a patient with pemphigus vulgaris and squamous cell carcinoma of the tongue and IgG antibodies to desmocollins","volume":"69","author":"Kim","year":"2013","journal-title":"J. Am. Acad. Dermatol."},{"issue":"7","key":"10.1016\/j.intimp.2017.11.005_bb0380","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/j.1365-4632.2012.5847.x","article-title":"Adjuvant rituximab in the treatment of pemphigus vulgaris: a phase II clinical trial","volume":"52","author":"Balighi","year":"2013","journal-title":"Int. J. Dermatol."},{"issue":"4","key":"10.1016\/j.intimp.2017.11.005_bb0385","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1590\/abd1806-4841.20131990","article-title":"Severe multi-resistant pemphigus vulgaris: prolonged remission with a single cycle of rituximab","volume":"88","author":"Corral","year":"2013","journal-title":"An. Bras. Dermatol."},{"issue":"4","key":"10.1016\/j.intimp.2017.11.005_bb0390","doi-asserted-by":"crossref","first-page":"472","DOI":"10.2340\/00015555-1746","article-title":"First-line combination therapy with rituximab and corticosteroids is effective and safe for pemphigus","volume":"94","author":"Cho","year":"2014","journal-title":"Acta Derm. Venereol."},{"issue":"4","key":"10.1016\/j.intimp.2017.11.005_bb0395","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.pedneo.2013.08.008","article-title":"Oral ulcers as an initial presentation of juvenile pemphigus: a case report","volume":"57","author":"Chen","year":"2016","journal-title":"Pediatr. Neonatol."},{"issue":"7","key":"10.1016\/j.intimp.2017.11.005_bb0400","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1001\/jamadermatol.2013.6739","article-title":"Durable remission of pemphigus with a fixed-dose rituximab protocol","volume":"150","author":"Heelan","year":"2014","journal-title":"JAMA Dermatol."},{"issue":"2","key":"10.1016\/j.intimp.2017.11.005_bb0405","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1159\/000357031","article-title":"Pilot study of 19 patients with severe pemphigus: prophylactic treatment with rituximab does not appear to be beneficial","volume":"228","author":"Gregoriou","year":"2014","journal-title":"Dermatology"},{"issue":"6","key":"10.1016\/j.intimp.2017.11.005_bb0410","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1111\/bjd.12972","article-title":"Clinical and immunological outcomes of high- and low-dose rituximab treatments in patients with pemphigus: a randomized, comparative, observer-blinded study","volume":"170","author":"Kanwar","year":"2014","journal-title":"Br. J. Dermatol."},{"issue":"9","key":"10.1016\/j.intimp.2017.11.005_bb0415","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1111\/jdv.12536","article-title":"Pemphigus vulgaris of the epiglottis successfully treated with rituximab","volume":"29","author":"Gregoriou","year":"2015","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"4","key":"10.1016\/j.intimp.2017.11.005_bb0420","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jaad.2014.05.071","article-title":"Successful use of rituximab in the treatment of childhood and juvenile pemphigus","volume":"71","author":"Vinay","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"issue":"4","key":"10.1016\/j.intimp.2017.11.005_bb0425","doi-asserted-by":"crossref","first-page":"300","DOI":"10.4103\/0378-6323.136832","article-title":"Intermediate doses of rituximab used as adjuvant therapy in refractory pemphigus","volume":"80","author":"Londhe","year":"2014","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"issue":"3","key":"10.1016\/j.intimp.2017.11.005_bb0430","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/bjd.13307","article-title":"Rituximab in patients with recalcitrant autoimmune blistering diseases: experience in a cohort of 22 patients","volume":"172","author":"Tomsitz","year":"2015","journal-title":"Br. J. Dermatol."},{"issue":"1","key":"10.1016\/j.intimp.2017.11.005_bb0435","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/jdv.12622","article-title":"Novel presentation of rituximab-induced herpes zoster: urinary retention and acute kidney failure","volume":"30","author":"Diernaes","year":"2016","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"3","key":"10.1016\/j.intimp.2017.11.005_bb0440","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1038\/jid.2014.291","article-title":"Persistence of anti-desmoglein 3 IgG(+) B-cell clones in pemphigus patients over years","volume":"135","author":"Hammers","year":"2015","journal-title":"J. Invest. Dermatol."},{"issue":"5","key":"10.1016\/j.intimp.2017.11.005_bb0445","doi-asserted-by":"crossref","first-page":"422","DOI":"10.4103\/0378-6323.140301","article-title":"Use of rituximab in pemphigus patients with chronic viral hepatitis: report of three cases","volume":"80","author":"Kanwar","year":"2014","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"issue":"6","key":"10.1016\/j.intimp.2017.11.005_bb0450","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1590\/abd1806-4841.20143128","article-title":"Refractory pemphigus vulgaris treated with rituximab and mycophenolate mofetil","volume":"89","author":"Biot Sdel","year":"2014","journal-title":"An. Bras. Dermatol."},{"issue":"3","key":"10.1016\/j.intimp.2017.11.005_bb0455","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/imj.12674","article-title":"Treatment outcomes in a cohort of patients with mucosal-predominant pemphigus vulgaris","volume":"45","author":"Ojaimi","year":"2015","journal-title":"Intern. Med. J."},{"issue":"4","key":"10.1016\/j.intimp.2017.11.005_bb0460","first-page":"288","article-title":"Resolution of a case of pediatric pemphigus vulgaris treated with rituximab","volume":"22","author":"Didona","year":"2014","journal-title":"Acta Dermatovenerol. Croat."},{"key":"10.1016\/j.intimp.2017.11.005_bb0465","doi-asserted-by":"crossref","first-page":"65","DOI":"10.12659\/AJCR.892635","article-title":"Brain abscess following rituximab infusion in a patient with pemphigus vulgaris","volume":"16","author":"Al-Harbi","year":"2015","journal-title":"Am. J. Case Rep."},{"issue":"6","key":"10.1016\/j.intimp.2017.11.005_bb0470","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1111\/jdv.13103","article-title":"Rituximab in the treatment of 38 patients with pemphigus with long-term follow-up","volume":"30","author":"Currimbhoy","year":"2016","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"6","key":"10.1016\/j.intimp.2017.11.005_bb0475","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1111\/bjd.13990","article-title":"Complete remission after rituximab therapy in an HIV-positive patient with pemphigus vulgaris","volume":"173","author":"Polansky","year":"2015","journal-title":"Br. J. Dermatol."},{"issue":"6","key":"10.1016\/j.intimp.2017.11.005_bb0480","doi-asserted-by":"crossref","DOI":"10.5070\/D3236035399","article-title":"Rituximab administration in a patient with pemphigus vulgaris following reactivation of occult hepatitis B virus infection","volume":"23","author":"Tavakolpour","year":"2017","journal-title":"Dermatol. Online J."},{"issue":"6","key":"10.1016\/j.intimp.2017.11.005_bb0485","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1111\/pde.12684","article-title":"Retrospective study on autoimmune blistering disease in paediatric patients","volume":"32","author":"Kong","year":"2015","journal-title":"Pediatr. Dermatol."},{"key":"10.1016\/j.intimp.2017.11.005_bb0490","first-page":"109","article-title":"Rituximab therapy improves recalcitrant pemphigus vulgaris","volume":"14","author":"Noormohammadpour","year":"2015","journal-title":"EXCLI J."},{"issue":"6","key":"10.1016\/j.intimp.2017.11.005_bb0495","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1684\/ejd.2015.2652","article-title":"The pathogenic activity of anti-desmoglein autoantibodies parallels disease severity in rituximab-treated patients with pemphigus vulgaris","volume":"25","author":"Sinistro","year":"2015","journal-title":"Eur. J. Dermatol."},{"issue":"6","key":"10.1016\/j.intimp.2017.11.005_bb0500","doi-asserted-by":"crossref","first-page":"444","DOI":"10.4103\/2229-5178.169722","article-title":"Rituximab therapy in a case of pemphigus vulgaris triggering herpes simplex infection at varied sites","volume":"6","author":"Chotaliya","year":"2015","journal-title":"Indian Dermatol. Online J."},{"issue":"2","key":"10.1016\/j.intimp.2017.11.005_bb0505","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1111\/pde.12744","article-title":"Rituximab therapy for childhood pemphigus vulgaris","volume":"33","author":"Kincaid","year":"2016","journal-title":"Pediatr. Dermatol."},{"key":"10.1016\/j.intimp.2017.11.005_bb0510","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.intimp.2016.02.013","article-title":"First line treatment of pemphigus vulgaris with a novel protocol in patients with contraindications to systemic corticosteroids and immunosuppressive agents: preliminary retrospective study with a seven year follow-up","volume":"34","author":"Ahmed","year":"2016","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2017.11.005_bb0515","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12959-016-0080-6","article-title":"Recurrent venous thrombosis in an adequately anticoagulated patient with pemphigus vulgaris","volume":"14","author":"Ames","year":"2016","journal-title":"Thromb. J."},{"issue":"5","key":"10.1016\/j.intimp.2017.11.005_bb0520","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/ced.12842","article-title":"Crescendo response to rituximab in oral pemphigus vulgaris: a case with 7-year follow-up","volume":"41","author":"Greenblatt","year":"2016","journal-title":"Clin. Exp. Dermatol."},{"issue":"5","key":"10.1016\/j.intimp.2017.11.005_bb0525","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1159\/000448031","article-title":"Assessment of the effects of rituximab monotherapy on different subsets of circulating T-regulatory cells and clinical disease severity in severe pemphigus vulgaris","volume":"232","author":"Bhattacharjee","year":"2016","journal-title":"Dermatology"},{"issue":"10","key":"10.1016\/j.intimp.2017.11.005_bb0530","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1111\/jdv.13330","article-title":"Successful use of etanercept in a case of toxic epidermal necrolysis induced by rituximab","volume":"30","author":"Didona","year":"2016","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.intimp.2017.11.005_bb0535","first-page":"1","article-title":"Rituximab treatment of pemphigus in women of childbearing age: experience with two patients","author":"Lake","year":"2016","journal-title":"J. Dermatol. Treat."},{"key":"10.1016\/j.intimp.2017.11.005_bb0540","doi-asserted-by":"crossref","first-page":"e331","DOI":"10.1111\/jdv.14119","article-title":"Pregnancy outcome after rituximab treatment before conception in patients affected by severe pemphigus vulgaris\/superficialis","volume":"31","author":"Vassallo","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"12","key":"10.1016\/j.intimp.2017.11.005_bb0545","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1111\/ijd.13400","article-title":"Efficacy and safety of rituximab therapy in patients with pemphigus vulgaris: first report from Turkey","volume":"55","author":"Uzun","year":"2016","journal-title":"Int. J. Dermatol."},{"key":"10.1016\/j.intimp.2017.11.005_bb0550","doi-asserted-by":"crossref","first-page":"e350","DOI":"10.1111\/jdv.14144","article-title":"Fatal infection of Pneumocystis jiroveci pneumonia in a pemphigus patient treated with rituximab","volume":"31","author":"Wei","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"6","key":"10.1016\/j.intimp.2017.11.005_bb0555","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/1346-8138.13757","article-title":"Adjuvant rituximab treatment for pemphigus: a retrospective study of 45 patients at a single center with long-term follow up","volume":"44","author":"Kim","year":"2017","journal-title":"J. Dermatol."},{"key":"10.1016\/j.intimp.2017.11.005_bb0560","article-title":"Low-dose rituximab and concurrent adjuvant therapy for pemphigus: protocol and single-centre long-term review of nine patients","author":"Robinson","year":"2017","journal-title":"Australas J. Dermatol."},{"issue":"3","key":"10.1016\/j.intimp.2017.11.005_bb0565","doi-asserted-by":"crossref","first-page":"317","DOI":"10.4103\/ijdvl.IJDVL_1078_14","article-title":"Low-dose rituximab as an adjuvant therapy in pemphigus","volume":"83","author":"Gupta","year":"2017","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"issue":"4-5","key":"10.1016\/j.intimp.2017.11.005_bb0570","first-page":"E35","article-title":"Nasal, pharyngeal, and laryngeal pemphigus vulgaris successfully treated with rituximab","volume":"96","author":"Sami","year":"2017","journal-title":"Ear Nose Throat J."},{"issue":"4","key":"10.1016\/j.intimp.2017.11.005_bb0575","first-page":"wc01","article-title":"Rituximab: a magic bullet for pemphigus","volume":"11","author":"Anandan","year":"2017","journal-title":"J. Clin. Diagn. Res."},{"key":"10.1016\/j.intimp.2017.11.005_bb0580","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s00403-017-1754-z","volume":"309","author":"El-Zawahry","year":"2017","journal-title":"Arch. Dermatol. Res."},{"issue":"6","key":"10.1016\/j.intimp.2017.11.005_bb0585","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1684\/ejd.2012.1843","article-title":"Treatment of severe pemphigus vulgaris of the scalp with adjuvant rituximab and immunoadsorption","volume":"22","author":"Kamphausen","year":"2012","journal-title":"Eur. J. Dermatol."},{"issue":"4","key":"10.1016\/j.intimp.2017.11.005_bb0590","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1159\/000099591","article-title":"Treatment of refractory pemphigus with the anti-CD20 monoclonal antibody (rituximab)","volume":"214","author":"Marzano","year":"2007","journal-title":"Dermatology"},{"issue":"8","key":"10.1016\/j.intimp.2017.11.005_bb0595","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1001\/jamadermatol.2014.3674","article-title":"Intralesional rituximab in the treatment of refractory oral pemphigus vulgaris","volume":"151","author":"Vinay","year":"2015","journal-title":"JAMA Dermatol."},{"issue":"12","key":"10.1016\/j.intimp.2017.11.005_bb0600","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.93222","article-title":"Robust memory responses against influenza vaccination in pemphigus patients previously treated with rituximab","volume":"2","author":"Cho","year":"2017","journal-title":"JCI Insight"},{"issue":"10","key":"10.1016\/j.intimp.2017.11.005_bb0605","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/j.1346-8138.2005.tb00862.x","article-title":"Severe pemphigus vulgaris treated with rituximab (Mabthera)","volume":"32","author":"Cecchi","year":"2005","journal-title":"J. Dermatol."},{"issue":"27","key":"10.1016\/j.intimp.2017.11.005_bb0610","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1056\/NEJMc1508234","article-title":"Long-term remissions in recalcitrant pemphigus vulgaris","volume":"373","author":"Ahmed","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.intimp.2017.11.005_bb0615","doi-asserted-by":"crossref","DOI":"10.1111\/aji.12601","article-title":"Management of pemphigus disease in pregnancy","volume":"77","author":"Tavakolpour","year":"2017","journal-title":"Am. J. Reprod. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2017.11.005_bb0620","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1610-0387.2007.06602.x","article-title":"Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases","volume":"6","author":"Hertl","year":"2008","journal-title":"J. Dtsch. Dermatol. Ges."},{"issue":"7","key":"10.1016\/j.intimp.2017.11.005_bb0625","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1001\/jamadermatol.2013.6739","article-title":"Durable remission of pemphigus with a fixed-dose rituximab protocol","volume":"150","author":"Heelan","year":"2014","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.intimp.2017.11.005_bb0630","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2017.07.012","article-title":"Developing biomarkers for predicting clinical relapse in pemphigus patients treated with rituximab","author":"Albers","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.intimp.2017.11.005_bb0635","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.imlet.2017.08.002","article-title":"Towards personalized medicine for patients with autoimmune diseases: opportunities and challenges","volume":"190","author":"Tavakolpour","year":"2017","journal-title":"Immunol. Lett."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576917304253?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576917304253?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T10:11:46Z","timestamp":1693217506000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576917304253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":127,"alternative-id":["S1567576917304253"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2017.11.005","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sixteen-year history of rituximab therapy for 1085 pemphigus vulgaris patients: A systematic review","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2017.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}